Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has experienced a decline in its stock price by -10.04 compared to its previous closing price of 58.95. However, the company has seen a fall of -0.58% in its stock price over the last five trading days. investorplace.com reported 2024-06-30 that Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don’t have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow.
Is It Worth Investing in Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) Right Now?
Additionally, the 36-month beta value for CRBP is 2.61. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRBP is 10.49M and currently, short sellers hold a 7.98% ratio of that float. The average trading volume of CRBP on July 19, 2024 was 281.71K shares.
CRBP’s Market Performance
The stock of Corbus Pharmaceuticals Holdings Inc (CRBP) has seen a -0.58% decrease in the past week, with a 19.95% rise in the past month, and a 42.71% gain in the past quarter. The volatility ratio for the week is 8.54%, and the volatility levels for the past 30 days are at 6.72% for CRBP. The simple moving average for the last 20 days is 7.01% for CRBP’s stock, with a simple moving average of 106.31% for the last 200 days.
Analysts’ Opinion of CRBP
Many brokerage firms have already submitted their reports for CRBP stocks, with B. Riley Securities repeating the rating for CRBP by listing it as a “Buy.” The predicted price for CRBP in the upcoming period, according to B. Riley Securities is $85 based on the research report published on June 26, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CRBP reach a price target of $80, previously predicting the price at $60. The rating they have provided for CRBP stocks is “Outperform” according to the report published on June 03rd, 2024.
RBC Capital Mkts gave a rating of “Outperform” to CRBP, setting the target price at $77 in the report published on May 13th of the current year.
CRBP Trading at 13.33% from the 50-Day Moving Average
After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.32% of loss for the given period.
Volatility was left at 6.72%, however, over the last 30 days, the volatility rate increased by 8.54%, as shares surge +21.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.60% upper at present.
During the last 5 trading sessions, CRBP fell by -0.58%, which changed the moving average for the period of 200-days by +686.80% in comparison to the 20-day moving average, which settled at $50.02. In addition, Corbus Pharmaceuticals Holdings Inc saw 777.98% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBP starting from Cohen Yuval, who sale 22,938 shares at the price of $42.24 back on Jun 18 ’24. After this action, Cohen Yuval now owns 77,221 shares of Corbus Pharmaceuticals Holdings Inc, valued at $968,832 using the latest closing price.
Moran Sean F., the Chief Financial Officer of Corbus Pharmaceuticals Holdings Inc, sale 1,958 shares at $42.12 during a trade that took place back on Jun 18 ’24, which means that Moran Sean F. is holding 48,605 shares at $82,479 based on the most recent closing price.
Stock Fundamentals for CRBP
Current profitability levels for the company are sitting at:
- -27.71 for the present operating margin
- 0.55 for the gross margin
The net margin for Corbus Pharmaceuticals Holdings Inc stands at -25.01. The total capital return value is set at -0.37. Equity return is now at value -59.52, with -38.06 for asset returns.
Based on Corbus Pharmaceuticals Holdings Inc (CRBP), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -1.67. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -72.24.
Currently, EBITDA for the company is -44.44 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 422.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.69.
Conclusion
In conclusion, Corbus Pharmaceuticals Holdings Inc (CRBP) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
